Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Debunking Myths in the US Healthcare System
Your Article Summary
See Latest ArticlesGiant cell tumour of bone
Current Opinion in Oncology, 06/18/09
Thomas DM et al. - In a study to determine new treatment options for pts with unresectable giant cell tumour of bone (GCT), it appears that denosumab presents a new treatment option for pts with previously untreatable GCT. The eventual role of denosumab and other targeted agents in the treatment of GCT and related disorders is currently the subject of active study.
Methods- Recent discoveries have identified a key role for the osteoclast differentiation factor, receptor activator of nuclear factor kappa B (NF-κB) ligand (RANKL), in the genesis of GCT.
- Development of the fully human monoclonal antibody to RANKL, denosumab, has led to a clinical trial in unresectable GCT.
- This study demonstrated an 86% response rate, with comparable evidence of clinical benefit, and was well tolerated.
- Other pathways that may present targets for therapy include the hypoxia-angiogenesis axis and the colony stimulating factor 1 receptor.
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI
The Journal of Nuclear Medicine, 08/19/09
Endoprosthetic proximal femur replacement: Metastatic versus primary tumors
Surgical Oncology, 11/05/09
Loss of p16INK4, alone and with overexpression of osteopontin, correlates with survival of patients with spinal metastasis from hepatocellular carcinoma
Medical Oncology, 10/19/09
Article Search
Sponsor